Quick Answer
Immuneering Corp reported Total Assets of $231.99 million for the year ending 2025.
- Immuneering Corp showed an increase of +340.1% in Total Assets from 2024 to 2025.
- This data is from Immuneering Corp's annual report (Form 10-K), filed with the SEC on March 6, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $53.04 million | Q3 2021: $164.04 million | Q1 2022: $152.45 million | Q2 2022: $142.05 million | Q3 2022: $133.69 million | Q1 2023: $107.70 million | Q2 2023: $124.90 million | Q3 2023: $113.88 million | Q1 2024: $87.98 million | Q2 2024: $77.09 million | Q1 2025: $50.68 million | Q2 2025: $40.06 million | Q3 2025: $241.06 million.
- Over the full 6 years of available data (2020 to 2025), Immuneering Corp's Total Assets has grown by 503.8%.
- Historical annual values: Fiscal year 2025: $231.99 million | Fiscal year 2024: $52.71 million | Fiscal year 2023: $102.58 million | Fiscal year 2022: $122.37 million | Fiscal year 2021: $166.70 million | Fiscal year 2020: $38.42 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: